CanSino Biologics, Inc. Class H (6185) Stock Statistics & Valuation Metrics

CanSino Biologics, Inc. Class H has a market cap or net worth of HK$16.57B. The enterprise value is HK$4.51B.

CanSino Biologics, Inc. Class H has 132,670,900 shares outstanding. The number of shares has decreased by -2.65% in one year.

CanSino Biologics, Inc. Class H’s return on equity (ROE) is <0.01 and return on invested capital (ROIC) is -1.76%.

The current PE Ratio of CanSino Biologics, Inc. Class H is 449.0. CanSino Biologics, Inc. Class H’s PEG ratio is -2.66.

In the last 12 months, CanSino Biologics, Inc. Class H had revenue of 1.03B and earned 27.15M in profits. Earnings per share was 0.11.

In the last 12 months, operating cash flow was 40.25M and capital expenditures -168.71M, giving a free cash flow of -128.37M billion.

CanSino Biologics, Inc. Class H pays an annual dividend of HK$0.937, resulting in a dividend yield of 1.31%

CanSino Biologics, Inc. Class H upcoming earnings date is Oct 28, 2026, TBA (Confirmed).

CanSino Biologics, Inc. Class H as a current ratio of 3.55, with Debt / Equity ratio of 19.69%

In the past 12 months, CanSino Biologics, Inc. Class H has paid -5.98M in taxes.

CanSino Biologics, Inc. Class H EV to EBITDA ratio is 131.20, with an EV/FCF ratio of -52.35.

CanSino Biologics, Inc. Class H has HK$1.84B in cash and marketable securities with HK$979.87M in debt, giving a net cash position of HK$863.54M billion.

Gross margin is 72.43%, with operating margin of -10.96%, and net profit margin of 2.63%.

The average price target for CanSino Biologics, Inc. Class H is HK$49.60, which is 11.43% higher than the current price. The consensus rating is Moderate Buy